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Pancreatic ductal adenocarcinoma (PDAC) is marked by an abundant stro-
mal deposition. This stroma is suspected to harbor both tumor-promoting
and tumor-suppressing properties. This is underscored by the disappointing
results of stroma targeting in clinical studies. Given the complexity of
tumor–stroma interaction in PDAC, there is a need to identify the stromal
proteins that are predominantly tumor-promoting. One possible candidate
is SPOCK1 that we previously identified in a screening effort in PDAC.
We extensively mined PDAC gene expression datasets, and used species-
specific transcript analysis in mixed-species models for PDAC to study the
patterns and driver mechanisms of SPOCK1 expression in PDAC.
Advanced organotypic coculture models with primary patient-derived
tumor cells were used to further characterize the function of this protein.
We found SPOCK1 expression to be predominantly stromal. Expression of
SPOCK1 was associated with poor disease outcome. Coculture and ligand
stimulation experiments revealed that SPOCK1 is expressed in response to
tumor cell-derived transforming growth factor-beta. Functional assessment
in cocultures demonstrated that SPOCK1 strongly affects the composition
of the extracellular collagen matrix and by doing so, enables invasive
tumor cell growth in PDAC. By defining the expression pattern and func-
tional properties of SPOCK1 in pancreatic cancer, we have identified a
stromal mediator of extracellular matrix remodeling that indirectly affects
the aggressive behavior of PDAC cells. The recognition that stromal pro-
teins actively contribute to the protumorigenic remodeling of the tumor
microenvironment should aid the design of future clinical studies to target
specific stromal targets.
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the
deadliest form of common cancer (Rahib et al., 2014).
Factors that contribute to its lethality include an
aggressive growth, high intrinsic resistance to (chemo)
therapeutics, and diagnosis at stages at which the
disease is no longer amenable to curative treatment
(Ghaneh et al., 2007; Hidalgo, 2010). Another feature
that is suspected to contribute to the poor outcome of
PDAC is the desmoplastic reaction, an extreme accu-
mulation of nonepithelial cells and material around
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the tumor cells (Waghray et al., 2013). These include
cancer-associated fibroblasts, activated stellate cells,
immune cells, but also the deposition of proteins like
collagen and fibrinogen that make up the extracellular
matrix. Together, these are known as the stroma. In
most cases of PDAC, the stromal fraction vastly out-
numbers the epithelium, and the bulk of the tumor is
typically not made up of tumor cells.
Histopathological assessment of activated stroma
has been shown to correlate with poor survival, and a
wealth of preclinical work has corroborated this
notion of a strictly tumor-promoting role for the
stroma (Fujita et al., 2010; Hwang et al., 2008;
Kadaba et al., 2013). For instance, the stiff mechanical
properties of the stroma reduce the perfusion of
PDAC tumors and this negatively affects delivery of
chemotherapeutics and also oxygen, causing hypoxia.
Furthermore, stromal cells have been described to act
as chaperones for tumor cells that disseminate from
the primary tumor, presumably providing a niche for
malignant cells that would otherwise be vulnerable
during transit (Coleman et al., 2014). In addition, we
and others have previously shown that the stroma pro-
vides a wide array of ligands that act in trans to sup-
port tumor cell growth (Damhofer et al., 2013).
Recent clinical trials using stroma-targeting agents
have failed to make good on the promise of preclinical
work; none of these trials have been reported to show
favorable responses, and one trial was interrupted fol-
lowing accelerated disease progression in the arm
receiving the experimental stroma-targeting agent
(BusinessWire, 2014). A tentative explanation for this
has come from later experimental work, which demon-
strated that the ablation of stroma from PDAC mouse
models resulted in enhanced aggressive growth and
chemoresistance of the tumor cells (Lee et al., 2014;
Ozdemir et al., 2014; Rhim et al., 2014). This is now
assumed to also occur in patients. It is possible that
the mechanical properties of the stroma keep the
tumor cells confined and in place, but it is also likely
that stromal trans-signaling molecules exist that keep
tumor cells relatively differentiated and inactive.
Which of the stromal contributions are required to
keep the tumor relatively indolent is not known. Con-
versely, which stromal factors have a specifically
tumor-promoting role is also not clear.
We have previously performed a screen for stromal
targets of tumor cell-derived Sonic Hedgehog (SHH), a
developmental protein important for the maintenance
of stroma in PDAC (Damhofer et al., 2013). From
this screen, several extracellular genes were identified
that were prognostic, and likely to support tumor
growth. One such gene was Sparc/osteonectin, Cwcv
and Kazal-like domains proteoglycan (SPOCK1).
SPOCK1 is a glycoprotein, highly similar to SPARC, a
well-studied and characterized protein in the context of
PDAC tumor growth (Hidalgo et al., 2015). Recently,
the significance of SPOCK1 for tumor growth, apopto-
sis, epithelial-to-mesenchymal transition (EMT), and
metastasis has been reported for tumor types other than
PDAC (Fan et al., 2016; Li et al., 2013; Ma et al., 2016;
Miao et al., 2013; Shu et al., 2015; Yang et al., 2016;
Yu et al., 2016). In these tumors, SPOCK1 appears to
predominately be expressed in the epithelial fraction.
We now demonstrate that in PDAC, the expression of
SPOCK1 is stromal rather than epithelial. We show that
its expression is driven by tumor cell-derived transform-
ing growth factor-beta (TGF-b) and that the function
of SPOCK1 is to translate the reception of this ligand
into stromal support for tumor cell growth and migra-
tion via the modulation of the extracellular collagen
matrix.
2. Materials and methods
2.1. Expression analysis
Datasets used were as follows (first author and contact
name for GEO or ArrayExpress submission are listed):
tumor expression data: GSE15471, Badea (Badea et al.,
2008); GSE16515, Pei/Wang (Pei et al., 2009);
GSE17891, Collisson/Sadanandam (Collisson et al.,
2011); GSE21501, Stratford/Yeh (Stratford et al., 2010);
GSE28735, Zhang/Hussain (Zhang et al., 2013);
GSE36924, Perez-Mancera/Wu (Bailey et al., 2016;
Perez-Mancera et al., 2012). Cell line expression data:
GSE21654, Maupin/Haab (Maupin et al., 2010);
GSE36133, Barretina/Stranksy (Barretina et al., 2012);
GSE57083, Wappett; E-MATB-783, Garnett/
McDermott (Garnett et al., 2012). Microdissected tissue
expression data: E-MEXP-1121, Pilarsky (Pilarsky et al.,
2008). Gene expression data were collected and processed
for use in the AMC in-house R2: Genomics Analysis and
Visualization Platform (http://r2.amc.nl). For visualiza-
tion of gene expression, data were imported in RSTUDIO
(RStudio Inc, Boston, MA, USA) and plotted using
GGPLOT2, or plotted in GRAPHPAD PRISM (Graphpad Soft-
ware Inc, La Jolla, CA, USA).
2.2. Gene set enrichment analysis
GSEA software (Broad Institute, Cambridge, MA,
USA) was downloaded from the Broad Institute web-
site (http://www.broad.mit.edu/gsea/) and gene sets
were obtained from the Molecular Signature Database
(MSigDB) and the Kyoto Encyclopedia of Genes and
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Genomes (KEGG). Expression datasets were assem-
bled with annotated gene names (.txt), samples were
dichotomized for median SPOCK1 expression to yield
phenotype label files (.cls), and gene sets were assem-
bled (.gmx). Two thousand permutations were run on
the phenotype. Datasets were not collapsed to gene
symbols in the GSEA software.
2.3. Tissue culture
Mouse embryonic fibroblasts (MEFs; kind gift from
Matthew Scott, Stanford University) and PANC-1
cells (ATCC) were cultured in DMEM containing 8%
FBS, L-glutamine (2 mM), penicillin (100 unitsmL1),
and streptomycin (500 lgmL1) according to routine
cell culture. The primary patient-derived cell line 67
was cultured in IMDM containing 8% FBS, L-gluta-
mine (2 mM), penicillin (100 unitsmL1), and strepto-
mycin (500 lgmL1). For cocultures, fibroblasts were
seeded in a 1 : 1 ratio with tumor cells at a total
amount of 20 000 cellscm2 and cultured for 7 days.
Prior to subsequent analyses, cells were imaged on a
Zeiss AxioVert microscope (Jena, Germany).
2.4. Lentiviral gene silencing
Lentivirus was produced by transfecting HEK293T
cells with Mission TRC library pLKO transfer plas-
mids together with the packaging plasmids pMD2.G
and psPAX2 using calcium phosphate. TRC clone
numbers used were as follows: 0000079969 and
0000079971. As a control, the shc002 scrambled plas-
mid was used. Forty-eight and 72 h after transfection,
supernatant was harvested and 0.45 lm filtered (Milli-
pore, Billerica, MA, USA). 60% confluent MEFs were
transduced with lentivirus and 5 lgmL1 polybrene
(Sigma, St. Louis, MO, USA) overnight. Two days
after transduction, MEFs were selected with
1 lgmL1 puromycin (Sigma).
2.5. Establishment of primary PDAC cell lines
The collection of patient material was approved by
the institute’s medical ethical committees (AMC
2014_181), and performed according to the guidelines
of the Helsinki Convention. Signed informed consent
was always obtained. Grafting of mice with patient
material was performed according to the protocols
approved by the Animal Experiment Ethical Commit-
tee (DTB102348). All surgical procedures were per-
formed under isoflurane anesthesia. For detailed
description of primary cell line isolation, propagation,
and characterization, see Damhofer et al. (2015).
2.6. Quantitative reverse transcriptase PCR
Following stimulations or cocultures, cells were har-
vested with trypsin/EDTA, and RNA was isolated using
the NucleoSpin RNA isolation kit (Macherey-Nagel,
D€uren, Germany) according to the manufacturer’s pro-
tocol. cDNA was synthesized using Superscript III
reverse transcriptase (ThermoFisher, Waltham, MA,
USA). Quantitative PCR was performed using Sybr
Green (Roche, Penzberg, Germany) on a Lightcycler
LC480 II (Roche). Data were normalized to GAPDH/
Gapdh transcript levels according to the comparative
threshold cycle (Cp) method. Primer sequences used
were as follows: hGAPDH Fw, aatcccatcaccatcttcca;
hGAPDH Rv, tggactccacgacgtactca; hSPOCK1 Fw,
aaagcacaaggcagaaagga; hSPOCK1 Rv, gggtcaagcaggag-
gtcata; mGapdh Fw, ctcatgaccacagtccatgc; mGapdh Rv,
cacattgggggtaggaacac; mSpock1 Fw, tgtgtgacccaggac-
tacca; mSpock1 Rv, tccaagccagtgtttgtgag; mGli1 Fw,
acacgggtgagaagccttac; mGli1 Rv, ggatctgtgtagcgcttggt;
mPtch1 Fw, gctacgactatgtctctcacatcaact; mPtch1 Rv,
ggcgacactttgatgaacca.
2.7. Ligand stimulation experiments
IL-1b was from Miltenyi; IL-1a and HGF were from
R&D; bFGF and EGF were from TEBU-BIO; TGF-b
was from Peprotech (Rocky Hill, NJ, USA). ShhN
was made by transfecting 293T cells with ShhN in
pRK5 (from Genentech, South San Francisco, CA,
USA) and after transfection, incubating cells in
DMEM containing 0.5% FBS. Prior to the addition
of ligands, cells were switched to 0.5% FBS culture
medium for 16 h. Ligands were added for 24 h.
2.8. Lentiviral cell labeling
pLeGO-V2 with Venus (plasmid #27340, Addgene
(Weber et al., 2011)) was used for lentivirus produc-
tion as described under Section 2.4. After overnight
transduction, cells were cultured for 72 h before
sorting for Venus-positive cells on a BD FACSAria
III.
2.9. Flow cytometry
Cells were harvested with trypsin/EDTA and washed
in FACS buffer (1% FBS/PBS). Cells were analyzed
with 1 lgmL1 PI and 10 lL CountBright absolute
counting beads (ThermoFisher, Waltham, MA, USA),
prepared following the manufacturer’s instructions,
and analyzed on FACSCanto II (BD). Data were ana-
lyzed using FLOWJO v10 (FlowJo LLC, Ashland, OR,
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USA). From the PI-negative fraction, the counts in the
Venus channel were analyzed and in the PerCP chan-
nel bead numbers were counted. The total amount of
beads added was divided by the beads acquired to
determine the multiplication factor required to accu-
rately determine the total amount of Venus-positive
cells in the culture.
2.10. Organotypic cultures
Organotypic cultures were performed according to
Kadaba et al. (2013). Tumor cells and fibroblasts were
plated in a 1 : 2 ratio on top of the gels, solidified on
nylon sheets, and grids placed at an air–liquid inter-
phase. Medium was replaced twice weekly. After cultur-
ing, gels were processed for both immunofluorescence
(IF) and immunohistochemistry (IHC). Gels were fixed
with 4% paraformaldehyde for 18 h after 1 week or
3 weeks, incubated in 20% sucrose, and mounted in
OCT (Tissue-Tek) for further processing for IF. For
IHC, gels were incubated in 70% ethanol after fixation,
and processed according to the standard procedures for
paraffin embedding.
2.11. Immunohistochemistry and staining
Tissue slides were stained as previously described on
the paraffin-embedded slides (Damhofer et al., 2015).
Antibodies and dilutions used were CK19 1 : 500
(MU246-UC; Biogenex), CXCR4 1 : 400 (Ab124824;
Abcam, Cambridge, UK), Ki67 1 : 2000 (SAB5500134;
Sigma). For picrosirius red staining, slides were
deparaffinized, stained in a 0.1% picrosirius red solu-
tion (Sigma) in saturated picric acid for 1 h, and
washed three times with 0.1 M acetic acid solution. All
slides were imaged on an Olympus BX51 (Tokyo,
Japan). Quantification of Ki67 staining was per-
formed with Fiji count particles (Schindelin et al.,
2012), after DAB/H color deconvolution. For IF
images, slides were cut at 10 lm, mounted in Prolong
Gold (ThermoFisher), and imaged on an EVOS fluo-
rescence microscope (ThermoFisher). For collagen
staining in tissue culture vessels, cells were cultured as
described and after 7 days of coculture washed with
PBS three times prior to fixation in 4% paraformalde-
hyde for 15 min. Following three washes with PBS,
cells were stained for their collagen deposition as
described above for 18 h and were equally treated as
the tissue slides. Cells were subsequently imaged on
an Olympus BX51. Quantifications of the percentage
of Ki67-positive nuclei, width of HE staining, or per-
centage of Venus-positive cells were performed using
Fiji package of IMAGEJ.
3. Results
3.1. SPOCK1 is upregulated in pancreatic cancer
and its expression is confined to the stroma
Using cocultures of human tumor cells and mouse
fibroblasts to model the stroma, followed by species-
specific RNA-Seq analysis, we have previously identi-
fied mouse Spock1 as a stromal target gene of tumor
cell-derived SHH (Damhofer et al., 2013). In our pre-
vious screen hit selection, we included only those genes
that were prognostic in the Badea et al.’s (2008)
PDAC cohort. To validate that SPOCK1 expression is
also prognostic in other cohorts, we dichotomized
patients included in additional expression datasets by
median and performed survival analysis (Stratford
et al., 2010; Zhang et al., 2013) (Fig. S1A). In the
Stratford et al.’s cohort, SPOCK1 expression higher
than median correlated with poor prognosis. Survival
analysis on groups dichotomized by scanning for the
best prognostic separation yielded highly significant
differences in survival outcome in both cohorts
(Fig. S1B). These results demonstrate that SPOCK1 is
correlated with poor prognosis in multiple datasets
and that a stromal gene can be strongly prognostic.
Our previous analyses did not exclude the possibility
that SPOCK1 is also expressed in the tumor cells in
PDAC. To further delineate the source of SPOCK1 in
human tumors and confirm its expression to be con-
fined to tumor stroma, we performed extensive analy-
sis on publically available gene expression data. First,
we assessed SPOCK1 expression across microarray
datasets that include normal pancreas samples and
pancreatic cancer tissue (Badea et al., 2008; Pei et al.,
2009; Zhang et al., 2013). SPOCK1 was significantly
upregulated in tumor tissue compared to nontumor
samples (Fig. 1A). However, when including expres-
sion data from purely epithelial PDAC cell lines (Bar-
retina et al., 2012; Garnett et al., 2012; Maupin et al.,
2010), SPOCK1 expression was found significantly
lower or absent in these samples, suggesting a stromal
expression pattern for SPOCK1 (Fig. 1A; gray box-
plots). These findings were corroborated in microdis-
sected tumor tissue (Pilarsky et al., 2008), where
SPOCK1 expression was predominantly expressed in
the nonepithelial fraction (Fig. 1B).
Gene expression-based subgroups have been identified
in PDAC. For instance, Collisson et al. (2011) demon-
strated the existence of three PDAC subtypes, including a
poor-prognosis quasi-mesenchymal (QM) subtype char-
acterized by EMT-associated genes. This subgroup identi-
fication was predominantly established using tumor cells
and microdissected tumor tissue, and the QM signature
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in the classified samples was therefore not confounded by
stromal infiltration. We did not find SPOCK1 to be sig-
nificantly higher in the samples classified as QM com-
pared to the other subtypes, establishing that SPOCK1
expression is stromal rather than a hallmark of tumor
cells of a mesenchymal phenotype (Fig. 1C).
In bulk tumor-derived expression data, we found a
very strong correlation of SPOCK1 expression with
markers of activated stroma (Fig. 1D): secreted pro-
tein acidic and cysteine rich (SPARC), a-smooth mus-
cle actin (aSMA/ACTA2), and fibroblast activation
protein. We found no obvious or consistent inverse
correlation with tumor cell content as inferred from
cytokeratin 19 (KRT19), epithelial cell adhesion mole-
cule (EPCAM) and E-cadherin (CDH1) expression
(Fig. 1E), suggesting that the expression of stromal ac-
tivation markers including SPOCK1 is not the conse-
quence of increased stromal content.
3.2. SPOCK1 is a stromal target of TGF-b in PDAC
To experimentally confirm that indeed SPOCK1 is
expressed in tumor-instructed stromal cells, we cocul-
tured an immortalized human pancreatic stellate cell
line (PS-1; Froeling et al., 2009) with a previously
established PDAC cell lines (PANC-1 and MIA PaCa-
2) as well as a primary patient-derived tumor cell line
established in our laboratory (67; Damhofer et al.,
2015). Prior to the experiment, tumor cells were trans-
duced with a fluorophore to allow FACS-based sorting
and qRT-PCR on the stellate cells following the cocul-
ture (Fig. 2A). In all cocultures, an induction of
SPOCK1 expression in stellate cells was observed, con-
firming it to be a consistent target of tumor cell-
derived signals in stromal cells.
To further characterize the association of SPOCK1
expression with tumor biological processes specific to
PDAC, extensive additional GSEA on several gene
sets was performed using previously identified tissue-
or cell type-specific gene signatures (Table S1A)
(Moffitt et al., 2015). Of these, activated stroma genes
showed best enrichment across several datasets dichot-
omized for SPOCK1 expression. This was corrobo-
rated using previously established gene sets for PDAC
stromal infiltration and extracellular matrix in these
same analyses (Table S1B). The screen in which
SPOCK1 was identified relied on a blocking strategy
testing the requirement for SHH ligand, but left its
sufficiency untested (Damhofer et al., 2013). When
MEFs (as also used for (Damhofer et al., 2013)) were
treated with SHH ligand, induction of the target genes
Gli1 and Ptch1 was observed but no Spock1 induction
was detected (Fig. 2B). Gene set enrichment analysis
(GSEA) using previously established gene sets for
SHH signaling did not show convincing positive
enrichment scores in tumors with high SPOCK1
expression (Fig. 2C) (Zhao et al., 2002). In contrast,
GSEA with two Kyoto Encyclopedia of Genes and
Genomes (KEGG) gene sets for TGF-b, a ligand
known to mediate tumor–stroma crosstalk across
many cancer types, yielded good enrichment scores.
This suggested this ligand to be a likely candidate
inducer of SPOCK1 in PDAC stroma (Fig. 2D).
To functionally establish the relative potency of
TGF-b to induce SPOCK1 compared to other ligands
known to mediate tumor–stroma crosstalk in PDAC,
we applied a panel of such ligands to the PS-1 cells and
determined SPOCK1 levels by qRT-PCR (Fig. 2E). For
each ligand, we also determined their correlation with
SPOCK1 on microarray expression data (R2 values
plotted in the bars). Surprisingly, of all ligands tested,
only TGF-b was able to induce SPOCK1 expression.
Inhibitor experiments on cocultures of PANC-1 or 67
primary cells with stellate cells confirmed the role of
TGF-b in driving SPOCK1 expression; inhibition of the
TGF-b pathway using the small-molecule inhibitor
A83-01 efficiently blocked SPOCK1 expression
(Fig. 2F). These data suggest that the identification of
SPOCK1 in our initial in vitro screen relied on a combi-
nation of ligands in which SHH ligand was required but
not sufficient, and that TGF-b ligand is likely sufficient
to drive robust SPOCK1 expression.
Fig. 1. SPOCK1 is upregulated in pancreatic cancer and its expression is confined to the stroma. (A) Indicated microarray gene expression
datasets were queried for SPOCK1 expression levels (Badea et al., 2008; Pei et al., 2009; Zhang et al., 2013). Blue box plots indicate
normal (nontumor) pancreas samples, and red box plots indicate tumor samples. Gray box plots show expression in purely epithelial
pancreatic cancer cell lines (Barretina et al., 2012; Garnett et al., 2012; Maupin et al., 2010). Dots show individual samples; boxes indicate
median with first and third quartiles. Indicated P-values were determined by unpaired two-tailed Student’s t-test. Statistical significance for
cell lines versus tumor samples; P < 0.0001. (B) SPOCK1 levels in microdissected epithelial and surrounding tissue are shown (Pilarsky
et al., 2008). (C) As for panels A–B, on tumor samples classified using the PDAssigner classifier (Collisson et al., 2011). Subtypes are
indicated on x-axis. (D) Expression levels of stromal activation markers (log2) were correlated with SPOCK1 expression (on x-axis) (Badea
et al., 2008; Perez-Mancera et al., 2012; Zhang et al., 2013). Solid line indicates linear regression fit line, and shade area indicates standard
error confidence bounds. R-squared (R2) linear regression coefficients, determined using the R linear model function, and statistical
significance of regression are plotted next to dot color legends. (E) As for panel D, using epithelial marker genes.
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3.3. Stromal SPOCK1 affects collagen deposition
The identification of SPOCK1 as a stromal target for
tumor cell-derived ligands and its prognostic power
raise the question whether it has a functional role in
driving tumor biology. We applied lentiviral shRNA
silencing of Spock1 (shSpock1) in MEFs and verified
knockdown by qRT-PCR using species-specific primers
(Fig. 3A). Spock1 levels were almost undetectable in
monoculture of these MEFs, and coculturing MEFs
with tumor cells was necessary to induce expression.
By doing so, we were able to show efficient knock-
down of Spock1 by hairpin clones E3 and E5.
To test the effect of stromal Spock1 ablation on
tumor growth, Venus-expressing tumor cells and
shSpock1 MEFs were cocultured in two-dimensional
culture and the number of tumor cells was counted by
bead-normalized FACS (Fig. 3B). There was no effect
of shSpock1 on the number of PANC-1 tumor cells in
cocultures, and shSpock1 cocultures with 67 primary
cells showed only a modest decrease in the number of
tumor cells. Next, we tested the effect of coculturing
on resistance against therapeutics commonly used
against PDAC, gemcitabine and paclitaxel (Burris
et al., 1997; Goldstein et al., 2015; Von Hoff et al.,
2013). PANC-1 cells were resistant to the concentra-
tions used, and higher concentrations could not be
used as these were toxic to the MEFs (Fig. S2). How-
ever, as expected, cocultures of 67 primary PDAC cells
with control-silenced MEFs blunted the effect of
chemotherapeutics as compared to 67 primary cell
monocultures (Fig. 3C). However, no effect of
shSpock1 was observed in either coculture, and we
concluded that chemoresistance is not the mechanism
through which stromal SPOCK1 expression con-
tributes to poor prognosis in patients.
Prior to harvesting for FACS, cocultures were
imaged, and from these images, a much smaller size of
tumor cell colonies grown together with the shSpock1
MEFs was immediately apparent (cf. Fig. 3D). These
smaller colonies were seemingly incongruent with the
unchanged number of tumor cells as counted by FACS
(Fig. 3B), and implied that more tumor cells occupied
a smaller surface area in these Spock1-knockdown
cocultures. This observation, and the known interac-
tions of glycoproteins like SPOCK1 with the ECM,
led us to hypothesize that SPOCK1 could act on the
extracellular matrix and thereby indirectly affect the
growth pattern of the tumor cells. When collagen, a
major constituent of the PDAC extracellular matrix,
was visualized in the cocultures by picrosirius red,
marked differences were indeed apparent (Fig. 3F). In
shSpock1 cocultures, collagen fiber patterns were more
diffuse than in the control cocultures. Furthermore,
the MEF monolayer often grew on top of the tumor
cell colonies in the shSpock1 cocultures (as can be seen
from the foci of collagen in Fig. 3E, see also the distri-
bution of tumor cell colonies in Fig. 3D), whereas in
control cocultures, the tumor colonies typically
remained uncovered. These data suggest that by acting
on the extracellular collagen, stromal SPOCK1 affects
tumor cell growth and dispersal.
3.4. SPOCK1 affects invasive tumor cell growth
To more conclusively address the impact of stromal
SPOCK1 on tumor cell growth patterns, and for lack
of a feasible in vivo model to study this, we turned to
advanced organotypic culturing models (Froeling
et al., 2010). These cultures rely on an air–liquid inter-
face, optimized extracellular matrix composition, and
nutrient gradients to model conditions in tissue. In
addition, this method allows cocultures to grow over
much longer periods of time than two-dimensional
equivalents. In organotypic monocultures grown for
3 weeks, we observed differences in the growth
Fig. 2. SPOCK1 is a stromal target of tumor cell-derived TGF-b in PDAC. (A) PS-1-immortalized human stellate cells were cocultured with
indicated Venus fluorophore-expressing PDAC cell lines for 96 h. Cells were subsequently FACS-sorted and processed for qRT-PCR for
SPOCK1 and GAPDH. Shown is mean  SEM of SPOCK1 values relative to housekeeping gene. P-values were determined by unpaired
two-tailed Student’s t-test comparing control to tumor cell cocultures. (B) MEFs were serum-starved in 0.5% FBS and treated with ShhN
for 48 h. Transcript analysis for genes indicated on x-axis was performed. Bars show mean induction relative to control (set to 1)  SEM,
n = 3. (C) GSEA was performed using indicated gene expression dataset (Perez-Mancera et al., 2012). Samples were dichotomized by
median SPOCK1 expression. Gene sets for SHH signaling were from Zhao et al. (2002). See also Materials and methods, Section 2.2. (D)
GSEA was performed as for C, using two KEGG-derived TGF-b-related gene sets. (E) PS-1 cells were starved with 0.5% FBS for 24 h and
subsequently treated with the indicated ligands for 48 h. ShhN, 1 : 4 diluted 293T supernatant; HGF, 10 ngmL1; EGF, 50 ngmL1; bFGF,
10 ngmL1; IL-1a, 10 ngmL1; IL-1b, 10 ngmL1; TGF-b, 5 ngmL1. Number in bars indicates r-value of correlation of SPOCK1 with
transcripts coding for ligands used (dataset GSE28735 (Zhang et al., 2013)). Bars show mean SPOCK1 levels relative to GAPDH  SEM,
n = 3. Indicated P-value was determined by unpaired two-tailed Student’s t-test comparing control and TGF-b condition only. (F) PS-1 cells
were cocultured with indicated cancer cells and serum-starved as for E. TGF-b pathway inhibitor A38-01 was used at 1 lM. Bars show
mean SPOCK1 levels relative to GAPDH  SEM. At least triplicates are shown. Indicated P-values were determined by unpaired two-tailed
Student’s t-test comparing control and A83-01.
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patterns of the tumor cell lines as expected (Fig. 4A);
PANC-1 cells grew as a thick layer of epithelium,
whereas the 67 primary cells covered the collagen
matrix with a single layer of cells. Interestingly, the
shSpock1 MEF monocultures grew much less inva-
sively than the control MEFs did, suggesting that these
cells interact with matrix differently. The effects of
MEF monocultures on the collagen matrix were not
observed in short-term organotypic cultures (1 week;
Fig. 3A).
In PANC-1/MEF organotypic cocultures, a fairly
well-differentiated layer of epithelium could be
observed (Fig. 4B). The thickness of this layer was
much reduced in cocultures with shSpock1 MEFs, sug-
gesting a role for stromal SPOCK1 in facilitating
tumor growth. This was further supported by a
reduced number of Venus- and CK19-positive cells.
Proliferation, measured by IHC for Ki67, was reduced
in the shSpock1 MEF cocultures relative to control-
silenced cocultures (Fig. 4B,C, 15.89  1.13% versus
37.4  3.20%, P < 0.0001 by Student’s t-test). The 67
primary cell cocultures showed less tumor cell growth
in general, but the effect of shSpock1 in these cultures
mirrored that seen with the PANC-1 cells. A strong
reduction in proliferative index was observed in the
absence of stromal SPOCK1 (Fig. 4C–E, 14.83 
1.21% versus 38.25  1.26%, P < 0.0001).
To reveal the effects of shSpock1 on collagen com-
position in these organotypic cocultures, we used
picrosirius red staining and polarized light microscopy,
which allows the identification of the types of collagen
types (Lattouf et al., 2014). This analysis revealed that
indeed, control and shSpock1 cocultures exerted differ-
ential effects on the collagen matrix (Fig. S3B), sug-
gesting that Spock1 could alleviate the constraints
exerted on tumor cells by acting on the extracellular
matrix. Indeed, in the control PANC-1 organotypic
cocultures, we observed a tumor cell population that
had grown deep into the collagen matrix (Fig. 4B,
indicated by asterisks as well as by the perturbed
structure following sectioning). The increased expres-
sion of CXCR4 in this population suggests that these
cells constitute a relatively invasive population of
tumor cells. In the shSpock1 cocultures, this popula-
tion was notably absent, which implies that stromal
SPOCK1 also enables invasive growth of tumor cells.
The organotypic coculture data together with the anal-
yses of collagen composition show that SPOCK1 in
stromal cells functions to modify the collagen matrix
and thereby facilitates the invasive growth of tumor
cells. In the absence of SPOCK1, tumor cells are more
mechanically restricted by the matrix, possibly explain-
ing the prognostic value of SPOCK1 in PDAC.
4. Discussion
The contributions of the stroma to PDAC are strongly
diverse and now well recognized to include opposing
effects (systematically reviewed in Bijlsma and van
Laarhoven (2015)). A large number of studies have
demonstrated tumor-promoting contributions of the
stroma to PDAC growth, chemoresistance, and metas-
tasis. These effects are mediated, for instance, through
the mechanical restrictions that the dense stroma
exerts on tumor perfusion, or by the mixture of extra-
cellular stromal signals that shape a complex niche for
tumor cells to exist in. However, it has now become
clear that the stroma also holds tumor-restraining
properties. This was most apparent from recent unsuc-
cessful clinical trials using stroma-targeting drugs in
PDAC (BusinessWire, 2014; Kim et al., 2014). Experi-
mental work demonstrated that the ablation of stroma
from established tumors strongly increased aggressive
tumor growth (Lee et al., 2014; Ozdemir et al., 2014;
Fig. 3. Stromal SPOCK1 affects collagen deposition. (A) MEFs were transduced with a control scrambled shRNA (shc002) construct or with
constructs with shRNA sequences against Spock1. All five TRC clones showed efficient knockdown (average efficiency 88.3  8.5% SEM,
P = 0.01 by one-way ANOVA). Two clones were chosen for further experimentation: E3 and E5. Cells were cocultured with PANC-1 cells to
induce Spock1 to detectable levels. After 5-day coculture, cells were harvested and qRT-PCR was performed using species-specific primers.
Bars show mean Spock1 levels relative to Gapdh  SEM, n = 3. Difference between groups; P = 0.040. (B) MEFs were cocultured with
PANC-1 or 67 PDAC cell lines for 7 days and harvested for counting by bead-normalized FACS (see also Materials and methods,
Section 2.9). Shown are values normalized to shc002 control (set to 1), means  SEM, n = 5 or 6. Indicated P-value was determined by
unpaired two-tailed Student’s t-test comparing shc002 control and knockdown conditions. (C) Cultures with 67 primary PDAC cells grown in
total for 7 days as for B were treated with 0, 2, and 10 nM gemcitabine or 0, 2, and 2.5 nM paclitaxel for 5 days and the number of tumor
cells was counted by FACS. Shown are means  SEM, n = 2. Curves were fitted using GraphPad Prism; R2 indicates goodness of Fit. (D)
Cocultures as for B were imaged by brightfield and fluorescence microscopy. Overlays of both channels are shown. Scalebar: 200 lm. (E)
Quantification of Venus-positive area relative to shc002 control. Statistical significance was determined by unpaired two-tailed Student’s t-
test comparing to shc002. **P < 0.01; ***P < 0.005; ****P < 0.0001, n = 3. (F) As for B followed by picrosirius red staining and
visualization by brightfield microscopy. Scalebar: 200 lm.
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Fig. 4. SPOCK1 affects invasive tumor cell growth in organotypic cocultures. (A) Organotypic monocultures for the indicated cell lines were
grown for 3 weeks and processed for routine histopathology by hematoxylin and eosin (HE). Scalebar: 200 lm. (B) Organotypic (co)cultures
of PANC-1 cells with indicated cells were grown for 3 weeks and cultures were processed for immunofluorescence for transduced
fluorophore (Venus), HE, and immunohistochemistry for indicated proteins. Percentages in Ki67 represent nuclei positive, n = 2. Top row is
using shc002 control MEFs; bottom row is with shSpock1 MEFs. Scalebar: 200 lm. (C) Higher magnification of Ki67-stained specimens. (D,
E) As for B, using 67 primary PDAC cells. (F) Higher magnification of HE-stained PANC-1 and 67 cocultures, with quantification. P-values
were determined by unpaired two-tailed Student’s t-test comparing shc002 control and E5-knockdown clone.
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Rhim et al., 2014). It will therefore become important
to identify and target specific stromal genes that act
tumor-promoting, while leaving the tumor-restricting
features of the stroma intact.
In this study, we have addressed tumor-promoting
stromal factors and identified SPOCK1 as a mediator
of extracellular matrix remodeling and invasive tumor
growth. We demonstrated that stromal SPOCK1 does
not directly affect the chemoresistance of tumor cells,
but that stromal SPOCK1 does strongly contribute to
tumor growth and invasiveness in three-dimensional
cultures. Interestingly, these tumor-promoting effects
could not be revealed in classical two-dimensional
cocultures. It is possible that the longer culturing made
possible by organotypic cocultures is responsible for
this, but it is also possible that the tumor–stroma
interaction needs a three-dimensional configuration for
the growth-promoting effects of SPOCK1 to become
apparent.
We have shown that SPOCK1 affects tumor cells by
acting on the extracellular collagen, thereby facilitating
tumor cell expansion. This finding fits well with the
notion that stiffening of the extracellular matrix acts
on the proliferation, migration, and adhesion of tumor
cells (Butcher et al., 2009). Although signaling medi-
ated by collagen I – the major component of extracel-
lular matrix – has been demonstrated to increase the
clonogenic capacity of pancreatic tumor cells under
treatment with 5-FU, allowing chemoresistant clones
to grow out (Armstrong et al., 2004), we did not
observe an enhancement of the efficacy of gemcitabine
and paclitaxel following the ablation of SPOCK1. This
implies that the effects of shSpock1 in our experiments
are mediated through mechanical properties rather
than matrix-derived signaling molecules.
An important question left unexplored in this study
is the correlation of stromal SPOCK1 expression with
important tumor-promoting stromal features in patient
tumor material. Attempts by us to assess stromal
SPOCK1 by IHC revealed staining patterns that were
incongruent with the molecular data as shown in this
manuscript, and we propose that future studies on
large patient cohorts using novel, more specific, anti-
bodies or methods like in situ hybridization should be
used to address this.
The SPARC protein family, of which SPOCK1 is a
member, has diverse functions but all appear to be
involved in the regulation of extracellular matrix
aggregation and degradation. The role of SPARC in
tumorigenesis and growth varies. In PDAC, SPARC
signaling appears to be associated with tumor growth
suppression in vitro (Sato et al., 2003). Clinical studies,
however, showed a correlation between high stromal
SPARC expression and poor prognosis (Gundewar
et al., 2015). The results from our study (i.e., that
depletion of stromal SPOCK1 inhibits tumor cell pro-
liferation and invasion) are in apparent contrast to
what is found for stromal SPARC expression in
PDAC, emphasizing the complexity of the function of
these protein family members, and the PDAC extracel-
lular matrix in general.
Previous publications have demonstrated a role for
SPOCK1 in cancer types such as breast cancer (Fan
et al., 2016), prostate cancer (Chen et al., 2016; Yang
et al., 2015), glioblastomas (Yu et al., 2016), urothelial
carcinomas (Ma et al., 2016), ovarian cancer (Zhang
et al., 2015), esophageal squamous cell carcinomas
(Song et al., 2015), gallbladder cancer (Shu et al.,
2015), lung cancer (Miao et al., 2013), and hepatocel-
lular carcinomas (Li et al., 2013). All these studies
focused on the epithelial fraction. Instead, we find that
in PDAC, SPOCK1 is confined to the stromal com-
partment but indirectly affects the proliferation and
invasion of tumor cells. This indirect, extracellular
matrix-mediated effect of SPOCK1 could also explain
its correlation with poor prognosis in other (non-
PDAC) tumor types.
5. Conclusion
In conclusion, we have identified SPOCK1 as a stro-
mal protein that mediates tumor-promoting effects by
acting on the extracellular matrix, and propose that it
serves as consistent mediator of tumor-derived TGF-b
signaling across all cases of PDAC despite the hetero-
geneous genetic makeup of the tumor compartment.
The identification of specific tumor-promoting stromal
proteins can aid in the development of novel treatment
combinations, most likely on a backbone of cytotoxic
drugs. Furthermore, the expression of such proteins
can identify patients that harbor stroma of a particu-
larly malignant activation status, and be used for
stratification.
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